Combination of OK432 and human interferon-alpha for treating viral-induced diabetes mellitus in mice.
We investigated the therapeutic effects of OK432 (picibanil; CAS39325-1-4), an immunomodulator that is derived from the Su strain of Streptococcus pyogenes. This agent was administered alone or combined with human interferon-alpha in a murine model of insulin-dependent diabetes mellitus. Interferon-alpha inhibits viral replication, reducing the incidence of virus-induced IDDM. Groups of DBA/2 mice (N = 25 per group) received an intraperitoneal injection of OK432 and interferon-alpha daily for 16 d beginning 1 d after inoculation with 500 plaque-forming units of encephalomyocarditis virus (EMCV). The dose of OK432 was one clinical unit (corresponding to 0.1 mg dried cells) per mouse, and that of interferon-alpha was 1 x 10(4) u/g. The animals were killed at random at 3 or 7 d after inoculation with EMCV. The survival rate of mice treated with the combination of OK432 and with interferon-alpha was significantly greater than that of the non-treated infected control animals (P < 0.01). Fasting levels of blood glucose were significantly lower in the mice administered the combination, than in the controls, both on day 3 (68 +/- 21 mg/dl vs. 270 +/- 135 mg/dl, P < 0.01) and on day 7 (101 +/- 29 mg/dl vs. 219 +/- 112 mg/dl, P < 0.01). Serum levels of insulin were significantly higher in the treated mice than in the controls (65 +/- 5 vs. 55 +/- 1 microU/ml, P < 0.05). However, in the mice treated with OK432 or interferon-alpha alone, the survival rate and the blood level of glucose and insulin did not differ from those of infected controls. Natural killer (NK) cell activity was significantly higher in the mice treated with the drug combination than in the controls on both days evaluated: day 3, 65 +/- 5 vs. 55 +/- 1%, n = 3, P < 0.05; day 7, 44 +/- 3 vs. 22 +/- 8%, n = 3, P < 0.05). Serum levels of murine interferon in the treated mice exceeded those in controls on both days evaluated (day 3, 671 U/ml vs. 442 U/ml; day 7, 57 U/ml vs. 43 U/ml). There were no significant differences in NK cell activity or in the interferon level in mice treated with either OK432 or interferon-alpha alone as compared with the infected, non-treated controls. Results suggest that the combination of OK432 and interferon-alpha protects against virally induced IDDM by increasing the activity of NK cells as well as the plasma level of interferon.
Kanda
T
T
Department of Laboratory Medicine, Gunma University School of Medicine, Maebashi, Japan.
Kogure
S
S
Nara
M
M
Tsukui
S
S
Utsugi
T
T
Tomono
S
S
Kawazu
S
S
Nagai
R
R
Kobayashi
I
I
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight / Q000187:drug effects; D018188:Cardiovirus Infections / Q000150:complications* / Q000473:pathology / Q000821:virology; D002470:Cell Survival / Q000187:drug effects; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D004686:Encephalomyocarditis virus; D007328:Insulin / Q000097:blood; D007370:Interferon Type I / Q000494:pharmacology*; D007372:Interferons / Q000097:blood; D007694:Killer Cells, Natural / Q000187:drug effects; D008297:Male; D051379:Mice; D008811:Mice, Inbred DBA; D010179:Pancreas / Q000473:pathology / Q000821:virology; D010844:Picibanil / Q000494:pharmacology*; D011994:Recombinant Proteins; D016019:Survival Analysis
D001786:Blood Glucose; D007328:Insulin; D007370:Interferon Type I; D011994:Recombinant Proteins; D010844:Picibanil; D007372:Interferons